Natasha Wantulok, MD
Family Medicine · Pocahontas, ARNPI 1457747297
Payments from drug & device makers
Across 342 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tosoh Bioscience, Inc.$1K
- Novo Nordisk$1K
- AstraZeneca$792
- Amgen$561
- Novartis$385
- Lilly USA, LLC$296
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,79475%
- Education$1142%
- Gifts$1,45123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tosoh Bioscience, Inc. | 1 | $1,451 |
| Novo Nordisk | 73 | $1,047 |
| AstraZeneca | 39 | $792 |
| Amgen | 46 | $561 |
| Novartis | 31 | $385 |
| Lilly USA, LLC | 32 | $296 |
| AbbVie(2 entities) | 14 | $221 |
| Astellas Pharma US Inc | 9 | $208 |
| Bayer | 10 | $201 |
| GSK | 11 | $163 |
| Johnson & Johnson | 14 | $159 |
| Boehringer Ingelheim | 9 | $127 |
| Pfizer | 8 | $117 |
| Phathom Pharmaceuticals, Inc. | 9 | $87 |
| Sumitomo Pharma America, Inc. | 4 | $75 |
| Corcept Therapeutics | 3 | $68 |
| Merck | 4 | $51 |
| Sunovion Pharmaceuticals Inc. | 4 | $49 |
| Biohaven Pharmaceuticals, Inc. | 3 | $41 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Lundbeck LLC | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TSH, ST AIA-PACK$1,451
- PA, ST AIA-PACK$1,451
- SYMBICORT$102
- FARXIGA$102
How this compares
$6,359 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 120 | $120,377 |
| FarxigaDapagliflozin Propanediol | 175 | $120,110 |
| OzempicSemaglutide | 99 | $112,511 |
| RybelsusSemaglutide | 47 | $51,607 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $37,405 |
| MyrbetriqMirabegron | 100 | $37,150 |
| JanuviaSitagliptin Phosphate | 44 | $33,962 |
| EliquisApixaban | 62 | $32,745 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $31,762 |
| XareltoRivaroxaban | 46 | $27,657 |
| LinzessLinaclotide | 31 | $26,876 |
| MounjaroTirzepatide | 25 | $24,150 |
| TrulicityDulaglutide | 22 | $20,687 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $14,825 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $13,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Tresiba | $1,047 | $170,107163 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Pradaxa | $127 | $140,923175 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $792 | $139,189219 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix | $163 | $56,78797 claims |
| Lilly USA, LLCMounjaro, Trulicity | $296 | $44,83747 claims |
| Astellas Pharma US IncMyrbetriq | $208 | $37,150100 claims |
| MerckJanuvia | $51 | $33,96244 claims |
| PfizerEliquis | $117 | $32,74562 claims |
| Johnson & JohnsonXarelto | $159 | $27,65746 claims |
| AbbVieLinzess | $221 | $26,87631 claims |
| NovartisExelon | $385 | $8,25412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Pocahontas
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.